tiprankstipranks
Teva Pharmaceutical (GB:0LER)
LSE:0LER
UK Market
EarningsQ2 2026 Earnings Report

Teva Pharmaceutical (0LER) Q2 2026 Earnings Report

2 Followers

GB:0LER Q2 2026 EPS Results

Actual EPS$0.02
Consensus EPS$0.05
Beat/MissMissed by -$0.03
One Year Ago EPS$0.66

GB:0LER Q2 2026 Revenue Results

Actual Revenue$4.22B
Expected Revenue$4.02B
Beat/MissBeat by +$200.62M
YoY Revenue Growth-1.79%

Earnings Announcement Details

QuarterQ2 2026
Date07/29/2026
TimeBefore Open
Conference CallWednesday, July 29, 2026
GB:0LER Upcoming Earnings
Teva Pharmaceutical's next earnings date is estimated for November 11, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

GB:0LER Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Jul 29, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call skewed positive: the company showed strong, broad-based growth in its innovative portfolio (AUSTEDO, AJOVY, UZEDY) with multiple guidance increases, substantial free cash flow improvement (+31% YoY), margin expansion (gross margin +80 bps) and progressing pipeline and biosimilars commercialization that together materially reshape the company’s revenue mix and long-term outlook. Near-term challenges include a Q/Q revenue decline driven by the loss of generic REVLIMID, sizable one-time MLX acquisition charges that compressed reported margins and EPS, elevated AUSTEDO channel inventory and planned higher OpEx to support launches. Management framed these negatives as transitional (one-time or sequencing effects) while emphasizing durable growth drivers and credit-rating upgrades. On balance, the positive items (strong product growth, guidance raises, cash flow, pipeline progress and biosimilars momentum) outweigh the short-term headwinds.
Company Guidance
Management raised the midpoint of full‑year revenue guidance by $75 million and bumped product guidance for key innovators — AUSTEDO to $2.45–$2.60 billion (midpoint $2.5B, +$50M), UZEDY to $270–$290 million (+$15M) and AJOVY to $850–$870 million (+$90M) — bringing the three-product combined 2026 outlook to roughly $3.7 billion (≈17% growth vs. 2025). They reaffirmed ranges for operating profit, adjusted EBITDA, EPS and free cash flow, reiterated mid‑single digit revenue growth targets, a 30% non‑GAAP operating margin goal by 2027, and a net debt/EBITDA target below 2% (Q2 net debt $12.9B; net debt/EBITDA 2.8x, 2.3x ex‑MLX). 2026 non‑GAAP gross margin is guided to 54.5%–55.5% (Q2 was 55.4%, +80 bps Y/Y); OpEx is expected at ~28% of revenue; Q2 free cash flow was $622M (+31% Y/Y). They expect global generics flat to down low‑single digits ex‑generic REVLIMID, biosimilars on track to exceed $800M by 2027, and noted Q4 phasing assumptions (AUSTEDO Q4 YoY pressure related to IRA dynamics and inventory normalization; olanzapine initial Q4 volumes expected to be samples with no revenue).
Innovative Portfolio Strong Growth
Innovative revenue grew 43% YoY in Q2 2026. Key products: AUSTEDO up 40% YoY, UZEDY up 43% YoY, AJOVY up 56% YoY. Combined 2026 revenue outlook for AUSTEDO/AJOVY/UZEDY increased ~ $150M at the midpoint (~$3.7B combined, ~17% growth vs 2025).
AUSTEDO: Robust U.S. and Global Performance
AUSTEDO U.S. revenue $676M, up 33% YoY; global revenue up 40% YoY. TRx up 14% and milligram growth up 21%. AUSTEDO XR represents >60% of new patients. Full-year guidance for AUSTEDO raised $50M at the midpoint to $2.45B–$2.6B; management reiterated >$3B peak sales potential.
UZEDY Rapid Adoption
UZEDY revenue grew 43% YoY to $77M; TRx up 63% YoY. Risperidone LAI share nearly doubled from ~5% to ~10%; UZEDY capturing ~80% of the risperidone LAI market. Full-year guidance raised $15M at midpoint to $270M–$290M.
AJOVY Outperformance and Upsized Guidance
AJOVY Q2 global revenue $244M, up 56% YoY; U.S. revenue up 83% YoY driven by improved contracting, gross-to-net and market share gains. Full-year guidance increased $90M at midpoint to $850M–$870M with a path to $1B peak sales.
Pipeline and Near-Term Regulatory Catalysts
Company highlighted 5 potential submissions over 5 years and the potential to launch ~1 asset per year. Notable near-term catalysts: olanzapine LAI (FDA action anticipated Q4 2026; EU MAA accepted), ecopipane (submitted June for Tourette syndrome; potential H1 2027 launch), and multiple other Phase II/III readouts (DARI, duvaqito, anti-IL-15, celiac biopsy study).
Biosimilars Becoming a Growth Engine
Biosimilars portfolio expanded to 15 products in market and 14 in pipeline; management expects to double this in coming years. In the U.S., 2 of 5 products are #1 and a third is close; on track to exceed $800M by 2027.
Margin Improvement and Cash Generation
Non-GAAP gross margin increased by 80 basis points YoY to 55.4% in Q2 2026. Free cash flow was $622M in Q2, up 31% YoY. Management reiterated mid-single revenue growth goal, a 30% non-GAAP operating income target, net debt/EBITDA <2% by 2027, and 80% cash conversion.
Capital & Balance Sheet Progress and Ratings Upgrade
Net debt $12.9B (net debt/EBITDA 2.8x; excluding MLX impact 2.3x) with a clear path to the 2x target by 2027. Fitch upgraded Teva to investment grade and S&P/Moody’s outlooks improved, reflecting improved leverage and execution. Acquisition of Amylyx (MLX) closed in June; upfront consideration recorded as IP R&D expense but treated as investing cash flow (no FCF impact).

GB:0LER Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Nov 11, 2026
2026 (Q3)
0.71 / -
0.78
2026 (Q2)
0.05 / 0.02
0.66-96.97% (-0.64)
2026 (Q1)
0.47 / 0.53
0.521.92% (+0.01)
2025 (Q4)
0.64 / 0.96
0.7135.21% (+0.25)
2025 (Q3)
0.69 / 0.78
0.6913.04% (+0.09)
2025 (Q2)
0.62 / 0.66
0.618.20% (+0.05)
2025 (Q1)
0.46 / 0.52
0.488.33% (+0.04)
2024 (Q4)
0.71 / 0.71
1-29.00% (-0.29)
2024 (Q3)
0.66 / 0.69
0.615.00% (+0.09)
2024 (Q2)
0.55 / 0.61
0.568.93% (+0.05)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed